YERVOY 200 mg/40 ml, concentrate for solution for infusion

( ARTG ) Melanoma,YERVOY, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma. YERVOY, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. The approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. All analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,Renal Cell Carcinoma (RCC),YERVOY, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,Non-Small Cell Lung Cancer (NSCLC),YERVOY, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.,Malignant Pleural Mesothelioma (MPM),YERVOY, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,Oesophageal Squamous Cell Carcinoma (OSCC),YERVOY in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression equal to or greater than 1% as determined by a validated test.,Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) Colorectal Cancer (CRC),YERVOY in combination with nivolumab is indicated for the treatment of adult patients with unresectable or metastatic colorectal cancer (CRC) that is MSI-H or dMMR as determined by a validated test.,Hepatocellular Carcinoma (HCC),YERVOY, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma.